Ida B. Kristensen

Odense, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Title Not Found

Title Not Found

Journal: Ugeskrift for laeger

Published: August 06, 2026

Identifying High-Risk Smoldering Multiple Myeloma for Early Intervention.

Identifying High-Risk Smoldering Multiple Myeloma for Early Intervention.

Journal: JAMA oncology

Published: April 23, 2026

Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin Lymphoma.

Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin Lymphoma.

Journal: American journal of hematology

Published: November 01, 2025

Correction: Ibrutinib as treatment for Bing-Neel syndrome reclassified as glioblastoma: a case report.

Correction: Ibrutinib as treatment for Bing-Neel syndrome reclassified as glioblastoma: a case report.

Journal: Journal of medical case reports

Published: August 19, 2025

Ixazomib treatment has a dual effect on bone remodeling in patients with multiple myeloma: follow-up results from a phase 2 clinical study.

Ixazomib treatment has a dual effect on bone remodeling in patients with multiple myeloma: follow-up results from a phase 2 clinical study.

Journal: Bone

Published: March 31, 2025

Multiple myeloma: unplanned diagnostic pathways and association with risk factors and survival - a nationwide register-based cohort study in Denmark.

Multiple myeloma: unplanned diagnostic pathways and association with risk factors and survival - a nationwide register-based cohort study in Denmark.

Journal: BMC cancer

Published: May 27, 2024

Title Not Found

Title Not Found

Journal: Ugeskrift for laeger

Published: February 02, 2024

Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease.

Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease.

Journal: Cancers

Published: October 24, 2023

Ibrutinib as treatment for Bing-Neel syndrome reclassified as glioblastoma: a case report.

Ibrutinib as treatment for Bing-Neel syndrome reclassified as glioblastoma: a case report.

Journal: Journal of medical case reports

Published: March 28, 2023

Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study.

Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: December 02, 2022

Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients.

Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients.

Journal: European journal of haematology

Published: June 26, 2018

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma.

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma.

Journal: Experimental hematology & oncology

Published: June 09, 2018

Showing 1-12 of 22

Last Updated: 09/26/2026